Literature DB >> 19436934

Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women's Health Initiative randomized trial.

J A Cauley1, A Z LaCroix, J A Robbins, J Larson, R Wallace, J Wactawski-Wende, Z Chen, D C Bauer, S R Cummings, R Jackson.   

Abstract

INTRODUCTION: The purpose of the study was to test the hypothesis that the reduction in fractures with hormone therapy (HT) is greater in women with lower estradiol levels.
METHODS: We conducted a nested case-control study within the Women's Health Initiative HT Trials. The sample included 231 hip fracture case-control pairs and a random sample of 519 all fracture case-control pairs. Cases and controls were matched for age, ethnicity, randomization date, fracture history, and hysterectomy status. Hormones were measured prior to randomization. Incident cases of fracture were identified over an average follow-up of 6.53 years.
RESULTS: There was no evidence that the effect of HT on fracture differed by baseline estradiol (E2) or sex hormone binding globulin (SHBG). Across all quartiles of E2 and SHBG, women randomized to HT had about a 50% lower risk of fracture, including hip fracture, compared to placebo.
CONCLUSION: The effect of HT on fracture reduction is independent of estradiol and SHBG levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19436934      PMCID: PMC2787820          DOI: 10.1007/s00198-009-0953-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  34 in total

1.  Editorial: Sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid action?

Authors:  Sundeep Khosla
Journal:  J Clin Endocrinol Metab       Date:  2006-12       Impact factor: 5.958

2.  Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.

Authors:  Wulf H Utian; David F Archer; Gloria A Bachmann; Christopher Gallagher; Francine n Grodstein; Julia R Heiman; Victor W Henderson; Howard N Hodis; Richard H Karas; Rogerio A Lobo; JoAnn E Manson; Robert L Reid; Peter J Schmidt; Cynthia A Stuenkel
Journal:  Menopause       Date:  2008 Jul-Aug       Impact factor: 2.953

3.  Aromatase and breast cancer susceptibility.

Authors:  N M Probst-Hensch; S A Ingles; A T Diep; R W Haile; F Z Stanczyk; L N Kolonel; B E Henderson
Journal:  Endocr Relat Cancer       Date:  1999-06       Impact factor: 5.678

4.  Role of endocytosis in cellular uptake of sex steroids.

Authors:  Annette Hammes; Thomas K Andreassen; Robert Spoelgen; Jens Raila; Norbert Hubner; Herbert Schulz; Jochen Metzger; Florian J Schweigert; Peter B Luppa; Anders Nykjaer; Thomas E Willnow
Journal:  Cell       Date:  2005-09-09       Impact factor: 41.582

5.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.

Authors: 
Journal:  Control Clin Trials       Date:  1998-02

Review 6.  Epidemiology and outcomes of osteoporotic fractures.

Authors:  Steven R Cummings; L Joseph Melton
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

7.  Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.

Authors:  Somnath Sarkar; Bruce H Mitlak; Mayme Wong; John L Stock; Dennis M Black; Kristine D Harper
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

8.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Authors:  Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

9.  The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women.

Authors:  Natalia O Kuchuk; Natasja M van Schoor; Saskia M F Pluijm; Johannes H Smit; Willem de Ronde; Paul Lips
Journal:  Clin Endocrinol (Oxf)       Date:  2007-06-06       Impact factor: 3.478

10.  Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women.

Authors:  Alison J Huang; Bruce Ettinger; Eric Vittinghoff; Kristine E Ensrud; Karen C Johnson; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2007-11       Impact factor: 6.741

View more
  8 in total

1.  27-Hydroxycholesterol, an Endogenous SERM, and Risk of Fracture in Postmenopausal Women: A Nested Case-Cohort Study in the Women's Health Initiative.

Authors:  Po-Yin Chang; David Feldman; Marcia L Stefanick; Donald P McDonnell; Bonne M Thompson; Jeffrey G McDonald; Jennifer S Lee
Journal:  J Bone Miner Res       Date:  2018-12-07       Impact factor: 6.741

2.  Serum Sex Hormones and the Risk of Fracture Across the Menopausal Transition: Study of Women's Health Across the Nation.

Authors:  Jane A Cauley; Kristine Ruppert; Yinjuan Lian; Joel S Finkelstein; Carrie A Karvonen-Gutierrez; Sioban D Harlow; Joan C Lo; Sherri-Ann M Burnett-Bowie; Arun Karlamangla; Gail A Greendale
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

3.  Sex Steroid Hormones and Fracture in a Multiethnic Cohort of Women: The Women's Health Initiative Study (WHI).

Authors:  Jane A Cauley; Michelle E Danielson; Guru Rajesh Jammy; Doug C Bauer; Rebecca Jackson; Jean Wactawski-Wende; Rowan T Chlebowski; Kristine E Ensrud; Robert Boudreau
Journal:  J Clin Endocrinol Metab       Date:  2017-05-01       Impact factor: 5.958

Review 4.  Estrogens and Androgens in Skeletal Physiology and Pathophysiology.

Authors:  Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 5.  The role of leptin in regulating bone metabolism.

Authors:  Jagriti Upadhyay; Olivia M Farr; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-10-25       Impact factor: 8.694

6.  Sex hormone levels and risk of breast cancer with estrogen plus progestin.

Authors:  Ghada N Farhat; Neeta Parimi; Rowan T Chlebowski; Joann E Manson; Garnet Anderson; Alison J Huang; Eric Vittinghoff; Jennifer S Lee; Andrea Z Lacroix; Jane A Cauley; Rebecca Jackson; Deborah Grady; Dorothy S Lane; Lawrence Phillips; Michael S Simon; Steven R Cummings
Journal:  J Natl Cancer Inst       Date:  2013-09-16       Impact factor: 13.506

7.  Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer.

Authors:  Matthias Kalder; Peyman Hadji
Journal:  Breast Care (Basel)       Date:  2014-10       Impact factor: 2.860

8.  Systemic estradiol levels with low-dose vaginal estrogens.

Authors:  Richard J Santen; Sebastian Mirkin; Brian Bernick; Ginger D Constantine
Journal:  Menopause       Date:  2020-03       Impact factor: 3.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.